The Cancer Monoclonal Antibodies Market Growth 2022 - 2030
Cancer monoclonal antibodies are targeted immune cells that are identical clones of a single parent cell and specialized antibodies directed at particular cellular targets. Because of their special characteristics, monoclonal antibodies are thus very adaptable and play a significant part in treating malignant cells with a particular target. Therefore, it has been established that monoclonal antibodies are more efficient than other cancer therapy.
The market for cancer monoclonal antibodies in 2021 was USD 51.88 billion and will be worth USD 108.47 billion by 2030 at an 8.54% CAGR.
The market expansion is due to the rising incidence of cancer in the population. For instance, according to the World Health Organization, cancer accounted for around 9.6 million deaths in 2018 and is the second largest cause of death globally. Men are more likely to develop colon cancer, lung cancer, prostate cancer, and liver cancer than women, who are more likely to develop breast cancer, cervical cancer, colorectal cancer, and thyroid cancer.
Market Dynamics
Drivers
The rise in demand for ADCs is one of the major reasons for boosting the market for cancer monoclonal antibodies.
Antibodies are increasingly being chosen as the treatment of choice for conditions like inflammatory, oncological, and respiratory illnesses. A molecular understanding of illnesses increases the creation and application of antibodies. ADCs are increasingly being used, especially in radioimmunotherapy and antibody-directed enzyme prodrug therapy. The increasing use of these antibodies in drug development boosts revenue generation in the global next-generation biologics market, contributing to the expansion of the cancer monoclonal antibodies market.
Trends
Strategic alliances and partnership for R&D is the key trend influencing market growth for cancer monoclonal antibodies.
Strategic collaboration and licensing arrangements will aid in the development and commercialization of monoclonal antibodies worldwide. Co-development agreements allow both firms to use their technical skills to promote and support each other in developing and marketing innovative medications. They also provide appropriate funding for the companies engaged and lower liability costs for individual companies in the event of failure, attracting more venture capital.
Challenge
One of the major obstacles preventing the market expansion of cancer monoclonal antibodies is a complex regulatory environment. Obtaining regulatory approval is frequently challenging, unpredictable, and arbitrary. Before being approved and put on the market, biologic products must pass a variety of strict standards. Although such strict regulatory frameworks are advantageous for people, they also pose challenges and obstacles to the commercialization of the underlying products, particularly manufacturing and marketing approval.
Market Segmentation
On the basis of antibody type: the market for cancer monoclonal antibodies is segmented into chimeric antibodies, murine antibodies, humanized antibodies, and others. The humanized market segment maintained the largest position in the market in 2021 with 39.5% of revenue share Humanization of mouse monoclonal antibodies has been applied on a large scale due to the low cost, availability, and quick production time for mouse monoclonal antibodies, thereby driving the market growth. Additionally, humanized monoclonal antibodies make up 50% of recently authorized mAbs. Furthermore, the use of innovative genetic engineering technology in its manufacture is another potential growth driver for this segment.
In terms of application:
the cancer monoclonal antibodies market is segmented into brain cancer, breast cancer, liver cancer, colorectal cancer, blood cancer, and others. The blood cancer segment was the largest market contributor in 2021, with a 23.3% market share. There has been an increased need for therapies for hematological disorders, which has propelled the pharmaceutical industry to create cutting-edge drugs such as cancer monoclonal antibodies. For example, the FDA approved GSK's BLENREP in August 2020 for treating patients with relapsed or refractory multiple myeloma.
However, lung cancer will be the rapidly growing market segment with the highest CAGR due to the rising prevalence of lung cancer.
On the basis of end-user:
the market is segmented into pharmacies, research laboratories, hospitals & clinics, and others. In 2021, the hospital segment maintained the largest position in the market, with 39.7% of the revenue share, due to a rise in the number of patients admitted to hospitals for various chronic conditions. Demand for the product in hospitals will be driven by highly skilled experts delivering specialized therapies for ailments such as autoimmune disorders and cancer. Additionally, improving reimbursement practices for expensive therapies in hospitals will have an impact on patient visits.
Regionally:
North America was the largest market contributor, with 37.5% of the revenue share in 2021. It is due to factors like rising cancer rates and major FDA approvals for monoclonal antibodies. As per the Centers for Disease Control and Prevention, there will be 1.9 million new cases of cancer annually in the US by 2020, up from almost 1.5 million in 2010.
Key Players
- Novartis AG
- Johnson & Johnson
- Bristol Myers Squibb Company
- Genmab AS
- Eli Lilly and Company
- Seattle Genetics Inc.
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Amgen Inc.
- Spectrum Pharmaceuticals Inc.
The market for cancer monoclonal antibodies in 2021 was USD 51.88 billion and will be worth USD 108.47 billion by 2030 at an 8.54% CAGR. The rising incidence of cancer and developments in biomedical research are primary factors boosting market expansion.
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian